Close Menu

NEW YORK (GenomeWeb) – Illumina and Loxo Oncology said today that they plan to develop sequencing-based pan-cancer companion diagnostics for two of Loxo's targeted oncology drugs.

The companies will use a version of Illumina's TruSight 170 panel, a hybrid capture panel launched in the beginning of 2017 that analyzes both DNA and RNA. The test will be run on Illumina's NextSeq 550Dx platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
15
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing.